Burroughs Wellcome
Executive Summary
Acting VP-Marketing and Sales Jack Monroe temporarily replacing Pete Reckert, who left the firm in February "by mutual consent," according to Burroughs Wellcome. Monroe, who joined the firm as a sales rep in 1960, will resume his post as VP- organizational development when a permanent successor is found. . . . Carter-Wallace: Names former Sterling and Bristol-Myers exec John Hughes president, Carter Products Division. Hughes replaces John Mack, who will serve as corporate VP until he retires March 31, 1992. Hughes, 53, was most recently president and CEO of Vermont Castings. From 1962 to 1981 he held "various senior marketing and sales positions" with Sterling and Bristol-Myers, Carter-Wallace said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth